ATE363292T1 - Hydrogelzusammensetzungen mit kontrollierter freigabe von wachstumsfaktoren - Google Patents

Hydrogelzusammensetzungen mit kontrollierter freigabe von wachstumsfaktoren

Info

Publication number
ATE363292T1
ATE363292T1 AT99946759T AT99946759T ATE363292T1 AT E363292 T1 ATE363292 T1 AT E363292T1 AT 99946759 T AT99946759 T AT 99946759T AT 99946759 T AT99946759 T AT 99946759T AT E363292 T1 ATE363292 T1 AT E363292T1
Authority
AT
Austria
Prior art keywords
controlled release
growth factors
hydrogel compositions
compositions
physiologically acceptable
Prior art date
Application number
AT99946759T
Other languages
English (en)
Inventor
Robert Jennings
Bing Yang
Andrew Protter
Yu-Chang Wang
Original Assignee
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc filed Critical Scios Inc
Application granted granted Critical
Publication of ATE363292T1 publication Critical patent/ATE363292T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT99946759T 1998-09-04 1999-09-03 Hydrogelzusammensetzungen mit kontrollierter freigabe von wachstumsfaktoren ATE363292T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9916898P 1998-09-04 1998-09-04

Publications (1)

Publication Number Publication Date
ATE363292T1 true ATE363292T1 (de) 2007-06-15

Family

ID=22273280

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99946759T ATE363292T1 (de) 1998-09-04 1999-09-03 Hydrogelzusammensetzungen mit kontrollierter freigabe von wachstumsfaktoren

Country Status (13)

Country Link
US (1) US6331309B1 (de)
EP (1) EP1107791B8 (de)
JP (2) JP2002524425A (de)
AT (1) ATE363292T1 (de)
AU (1) AU758178B2 (de)
CA (1) CA2341410C (de)
CY (1) CY1107704T1 (de)
DE (1) DE69936212T2 (de)
DK (1) DK1107791T3 (de)
ES (1) ES2288024T3 (de)
IL (2) IL141688A0 (de)
PT (1) PT1107791E (de)
WO (1) WO2000013710A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178834B1 (de) * 1999-04-22 2006-01-04 Eidgenössische Technische Hochschule (ETH) Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen
AU2001263281A1 (en) * 2000-05-18 2001-11-26 Genetix Pharmaceuticals, Inc. Polyethylene glycol (peg) polymers for the promotion of angiogenesis
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
WO2003054146A2 (en) 2001-11-14 2003-07-03 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
JP2003238439A (ja) * 2002-02-13 2003-08-27 Yasuhiko Tabata 虚血治療剤
WO2003070749A2 (en) 2002-02-15 2003-08-28 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
US20030203032A1 (en) * 2002-04-25 2003-10-30 Schultz Clyde L. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
IL164822A0 (en) * 2002-04-25 2005-12-18 Rapidheal Inc Growth factor delivery system for the healing of wounds and the prevention and disease
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7361368B2 (en) 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
WO2004018628A2 (en) 2002-08-21 2004-03-04 Northwestern University Charged peptide-amphiphile solutions & self-assembled peptide nanofiber networks formed therefrom
JP2004115413A (ja) * 2002-09-25 2004-04-15 Yasuhiko Tabata 冠状動脈狭窄または閉塞治療用徐放性製剤
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
AU2003298647A1 (en) 2002-11-14 2004-06-15 Claussen, Randal, C. Synthesis and self-assembly of abc triblock bola peptide
EP1606065A4 (de) 2003-02-11 2010-09-29 Univ Northwestern Verfahren und materialien für nanokristalline oberflächenbeschichtungen und befestigung von amphiphilen peptid-nanofasern daran
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US7544661B2 (en) 2003-12-05 2009-06-09 Northwestern University Self-assembling peptide amphiphiles and related methods for growth factor delivery
US7452679B2 (en) 2003-12-05 2008-11-18 Northwestern University Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof
BRPI0518582A2 (pt) * 2004-11-24 2008-11-25 Therakine Corp implante para liberaÇço de medicamento intra-ocular
CA2598251A1 (en) 2005-03-04 2006-09-14 Northwestern University Angiogenic heparin binding peptide amphiphiles
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
CN102014957B (zh) 2008-04-21 2014-12-10 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US9248159B2 (en) 2008-10-14 2016-02-02 Robert Stanley Berman MRSA bactericidal topical gel
KR101101321B1 (ko) * 2008-11-03 2012-01-02 주식회사 엠씨티티 상처 치유를 위한 하이드로 겔 형태의 세포전달용 비히클 및 그 제조방법
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
AU2010236584A1 (en) 2009-04-13 2011-11-10 Northwestern University Novel peptide-based scaffolds for cartilage regeneration and methods for their use
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
EP3079668A1 (de) 2013-12-09 2016-10-19 Durect Corporation Pharmazeutisch aktive wirkstoffkomplexe, polymerkomplexe und zusammensetzungen und verfahren damit
WO2017116608A2 (en) * 2015-12-04 2017-07-06 President And Fellows Of Harvard College Devices, methods, and compositions for restricting cell position and stabilizing cells in culture systems
RU2020127792A (ru) 2018-01-26 2022-02-28 Дженентек, Инк. СЛИТЫЕ БЕЛКИ IL-22- Fc И СПОСОБЫ ПРИМЕНЕНИЯ
LT3743088T (lt) 2018-01-26 2022-12-27 F. Hoffmann-La Roche Ag Il-22 fc kompozicijos ir jų naudojimo būdai
SG11202007694UA (en) 2018-02-21 2020-09-29 Genentech Inc DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100271A (en) 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US5705485A (en) 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5100668A (en) * 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5013769A (en) * 1988-08-22 1991-05-07 Medipro Sciences Limited Method of making a hydrogel-forming wound dressing or skin coating material
US5470829A (en) 1988-11-17 1995-11-28 Prisell; Per Pharmaceutical preparation
FR2644066B1 (fr) 1989-03-09 1994-05-13 Therapeutiques Substitutives Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
EP0551626A1 (de) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible Gel als pharmazeutische Grundmasse für eine galenische Form
US5952006A (en) * 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
FR2740678B1 (fr) * 1995-11-06 1999-05-14 Oreal Utilisation en cosmetique d'une composition solide ayant une matrice gelifiee et compositions cosmetiques ou dermatologiques mises en oeuvre
CA2235025C (en) * 1996-08-16 2001-10-09 Mcw Research Foundation, Inc. Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues

Also Published As

Publication number Publication date
EP1107791A2 (de) 2001-06-20
AU5909599A (en) 2000-03-27
EP1107791B8 (de) 2007-11-07
JP2002524425A (ja) 2002-08-06
US6331309B1 (en) 2001-12-18
JP2011021045A (ja) 2011-02-03
CA2341410A1 (en) 2000-03-16
JP5576772B2 (ja) 2014-08-20
IL141688A (en) 2006-07-05
DK1107791T3 (da) 2007-09-03
WO2000013710A3 (en) 2000-06-02
ES2288024T3 (es) 2007-12-16
CA2341410C (en) 2007-11-20
EP1107791B1 (de) 2007-05-30
CY1107704T1 (el) 2013-04-18
AU758178B2 (en) 2003-03-20
PT1107791E (pt) 2007-07-06
IL141688A0 (en) 2002-03-10
DE69936212D1 (de) 2007-07-12
DE69936212T2 (de) 2008-01-24
WO2000013710A2 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
DE69936212D1 (de) Hydrogelzusammensetzungen mit kontrollierter freigabe von wachstumsfaktoren
DE69930763D1 (en) Tgf-g beta inhibitor-peptide
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
FR2752582B1 (fr) Compositions a base de polyorganosiloxanes a groupements fonctionnels reticulables et leur utilisation pour la realisation de revetements anti-adherents
EP1399501A4 (de) Negativ geladenes amphiphiles blockcopolymer als arzneistoffträger und komplex davon mit postitiv geladenem arzneistoff
CA2317441A1 (en) Intraocular lens coating compositions
MX9800350A (es) Composicion dispersante de polimero de tetrafluoroetileno.
MX193604B (es) Hidrogeles hidrofilicos altamente hinchables
EP1286823A4 (de) Ophtalmische linsen und zusammensetzungen und verfahren zu deren herstellung
BR0014417A (pt) Processo para preparação de uma mistura polimérica dispersada em água, mistura polimérica dispersada em água, composição para preparação de um revestimento resistente à água, e, artigo revestido resistente à água
AU4121597A (en) Cross-linked copolymers based on polycarboxylic polymers
CA2348495A1 (en) Intraocular lenses made from polymeric compositions
MXPA04002554A (es) Metodos y aparatos para revestir superficies para reducir la adsorcion de proteinas y la adhesion celular y presentar ligandos.
WO1999036100A3 (en) Polymeric carrier
FR2782520B1 (fr) Utilisation de dioxyde de titane comme agent anti-uv dans une composition de caoutchouc
ES2102175T3 (es) Combinaciones de polimeros para su utilizacion en lagrimas artificiales.
GB9828446D0 (en) Coating composition
AU1230800A (en) Controlled delivery of antidepressants
AU2003285488A1 (en) Derivatised hydrogels and their use
DE69614577D1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung
ES2189154T3 (es) Composiciones oftalmicas polimerizables in vivo.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1107791

Country of ref document: EP